Lucas GC holds extraordinary general meeting via webcast
Bitget2026/10/06 13:01Lucas GC held an extraordinary general meeting on Oct. 2, 2026, clearing all resolutions put to shareholders. Share consolidation ratification passed, confirming a 125-for-1 reverse split effective Sept. 1, 2026, with fractional shares rounded up. Share-consolidation charter update was ratified, alongside a bylaw change shortening deemed postal notice delivery to three calendar days. Share-capital restructuring was authorized: par-value reduction, subdivision of unissued shares, then an increase in authorized share count. Conditional authority was granted for additional reverse splits tied to share-price triggers, plus adoption of updated charter documents and adjournment authority. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucas GC Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045876), on October 06, 2026, and is solely responsible for the information contained therein.
- Lucas GC held an extraordinary general meeting on Oct. 2, 2026, clearing all resolutions put to shareholders.
- Share consolidation ratification passed, confirming a 125-for-1 reverse split effective Sept. 1, 2026, with fractional shares rounded up.
- Share-consolidation charter update was ratified, alongside a bylaw change shortening deemed postal notice delivery to three calendar days.
- Share-capital restructuring was authorized: par-value reduction, subdivision of unissued shares, then an increase in authorized share count.
- Conditional authority was granted for additional reverse splits tied to share-price triggers, plus adoption of updated charter documents and adjournment authority.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
